One Medication, Three Conditions: Why LDN Is Not a Silver Bullet for Long COVID, ME/CFS, and MCAS

Endorphin Depletion, Immune Dysregulation,

and the Limits of Pharmacological Optimism

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Introduction: The Allure of a Universal Solution

It is tempting to look at Low Dose Naltrexone (LDN) and see a single medication capable of addressing Long COVID (LC), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), and Mast Cell Activation Syndrome (MCAS) in one elegant stroke. After all, emerging evidence suggests that LDN demonstrates meaningful benefit across all three conditions. A 2026 systematic review and meta-analysis published in BMJ Open reported statistically significant improvements in fatigue, pain, cognitive function, and sleep quality among Long COVID clients treated with LDN (Byambasuren et al., 2026). A large retrospective study of 218 ME/CFS clients demonstrated a 73.9% positive response rate (Polo, 2019). And MCAS practitioners have increasingly incorporated LDN into layered treatment protocols, reporting encouraging clinical experience—though controlled MCAS-specific trials remain lacking.

That's a lot to ask from one medication.

The optimistic view—that since these conditions share a common endpoint of endorphin depletion, LDN should logically work for all of them—contains a grain of truth but oversimplifies a deeply complex clinical reality. Each of these conditions has distinct pathophysiological drivers, requires its own dedicated framework, and presents unique challenges that no single pharmacological agent can address alone. Perhaps most critically, a subset of individuals with the most severe endorphin depletion may actually be the very clients who cannot tolerate LDN—a clinical paradox that deserves serious attention.

Three Conditions, Three Frameworks

ME/CFS: The SHINE Framework

ME/CFS is best understood as an energy crisis at the cellular and neuroendocrine level, with hypothalamic dysfunction serving as a central organizing feature. One of the most established comprehensive frameworks is Dr. Jacob Teitelbaum's SHINE protocol—Sleep, Hormones, Infections/Inflammation, Nutrition, and Exercise as tolerated. In the developer's randomized, double-blind, placebo-controlled trial, 91% of ME/CFS and fibromyalgia clients improved using this approach, with an average 90% increase in quality of life (Teitelbaum et al., 2001). The mechanism of ME/CFS centers on mitochondrial energy failure, hypothalamic-pituitary-adrenal (HPA) axis dysregulation, and impaired restorative sleep. While immune dysfunction is present, it is generally regarded as secondary to the energy crisis rather than the primary driver. This distinction matters because it determines where therapeutic effort should be concentrated.

Long COVID: The Post-Infectious Immune Dysregulation Framework

Long COVID is best conceptualized as a hybrid condition—part ME/CFS energy crisis, part MCAS-driven immune dysregulation—triggered and sustained by post-infectious mechanisms. A review in Asia Pacific Allergy summarized that Long COVID involves multiple immune system perturbations including T-cell depletion, innate immune cell hyperactivity, depletion of naïve T and B cells, and elevated pro-inflammatory cytokines, alongside persistent viral reservoir and mast cell activation. Afrin and colleagues proposed that COVID-19 hyperinflammation may be rooted in mast cell activation syndrome (Afrin et al., 2020), and Weinstock and colleagues subsequently demonstrated that Long COVID clients present with virtually identical mast cell activation symptoms and severity as previously diagnosed MCAS clients (Weinstock et al., 2021). The practical consequence is that Long COVID treatment requires both the SHINE framework for the energy crisis component and a systematic MCAS-directed protocol for the immune dysregulation component. Neither alone is sufficient.

MCAS: The Immune Dysregulation Framework

MCAS represents a primary disorder of immune regulation characterized by mast cell hyperactivation and excessive mediator release—histamine, tryptase, prostaglandins, and leukotrienes—across multiple organ systems. Treatment follows a layered approach: H1/H2 antihistamine blockade, mast cell stabilizers, leukotriene inhibitors, and targeted immunomodulation. LDN occupies a specific niche within this layered protocol, not as a foundational therapy but as a modulatory adjunct acting through TLR4 antagonism and endorphin-mediated immune regulation.

The Endorphin Convergence: Where These Conditions Meet

Despite their distinct pathophysiology, all three conditions are proposed to converge on a common downstream endpoint: endorphin depletion.

The most direct evidence for this endpoint comes from ME/CFS and fibromyalgia. Panerai and colleagues (2002) found that peripheral blood mononuclear cell (PBMC) β-endorphin concentrations were significantly lower in CFS and fibromyalgia clients than in healthy controls (p < 0.001), while notably not depleted in clients with depression—suggesting endorphin depletion may be a candidate biomarker distinguishing neuroimmune fatigue states from mood disorders. Earlier work by Conti and colleagues (1998) reported that PBMC β-endorphin in CFS clients averaged 8.5 ± 7.0 compared to 42.6 ± 22.6 in healthy subjects—roughly a five-fold reduction. Both studies were small and preliminary, and comparable direct measurements in Long COVID and MCAS are not yet established; the extension to those conditions rests on shared inflammatory mechanisms rather than on measured β-endorphin data.

With that caveat, the proposed mechanisms driving endorphin depletion differ by condition while pointing toward a similar endpoint:

In ME/CFS, the energy crisis and HPA axis dysfunction may impair the hypothalamic-pituitary capacity to synthesize proopiomelanocortin (POMC), the precursor molecule from which β-endorphin is cleaved. Chronic non-restorative sleep—a hallmark of ME/CFS—can further deplete endorphin reserves through disrupted slow-wave sleep physiology.

In Long COVID, persistent immune activation and viral reservoir-driven inflammation are thought to place sustained demand on the endogenous opioid system, with mast cell activation compounding that demand through inflammatory mediator cascades.

In MCAS, chronic immune hyperactivation may function as a sustained endorphin drain, redirecting neuroendocrine resources away from endorphin synthesis toward acute-phase immune response and producing functional endorphin insufficiency even without primary opioid system pathology.

Because the proposed endpoint is similar, one can argue that LDN—which works primarily by transiently blocking opioid receptors to stimulate compensatory endorphin upregulation—should theoretically benefit all three conditions. This is the optimistic view, and it is not without merit.

How LDN Works—And Why the Mechanism Matters

LDN's therapeutic mechanism depends on a critical assumption: that the client's endogenous opioid system retains sufficient capacity to respond to transient receptor blockade with compensatory upregulation.

At doses of 1.5 to 4.5 mg taken at bedtime, naltrexone occupies opioid receptors for approximately four to six hours before being cleared. This brief blockade is interpreted by the neuroendocrine system as an endorphin deficit, triggering compensatory upregulation of both β-endorphin production and opioid receptor density. Once the drug clears, the combination of increased endorphin levels and enhanced receptor sensitivity is proposed to produce a net amplification of endogenous opioid signaling during the remaining 18 to 20 hours of the dosing cycle (Toljan & Vrooman, 2018).

Simultaneously, LDN antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages, reducing neuroinflammatory cytokine release—including TNF-α and IL-6—independent of its opioid receptor effects. Research on TRPM3 ion channel dysfunction in ME/CFS Natural Killer cells has demonstrated that LDN can restore TRPM3-like ionic currents, suggesting a third mechanism of action relevant to immune function (Cabanas et al., 2021).

This multi-mechanism profile is precisely what makes LDN so appealing across conditions. But it is also what makes the endorphin depletion paradox so clinically important.

The Endorphin Depletion Paradox: When LDN Fails the Clients Who Need It Most

Here is a clinical pattern the optimistic view can overlook—one best understood as a proposed model rather than an established mechanism. LDN's primary action—transient opioid blockade followed by compensatory endorphin rebound—requires a functional endorphin system capable of responding to the blockade signal.

In the majority of clients with LC, ME/CFS, or MCAS, the endorphin system appears to retain enough residual capacity to mount this compensatory response. These clients tolerate LDN well, experience the expected rebound upregulation, and report clinical improvement. This is consistent with the response rates seen in ME/CFS, where roughly three-quarters of clients in one large observational cohort reported benefit (Polo, 2019).

But in a clinically significant minority—those with the most severe and prolonged endorphin depletion—the system may be pushed beyond its compensatory capacity. Chronic, unrelenting inflammatory demand from sustained MCAS activation, prolonged ME/CFS energy crisis, or the compounded burden of Long COVID may exhaust the neuroendocrine machinery responsible for endorphin synthesis. In these individuals, the transient opioid blockade imposed by LDN may fail to trigger a compensatory rebound. Instead, it can create a temporary endorphin vacuum—blocking the few endorphins still circulating without generating the expected replacement surge.

The clinical presentation of this proposed paradox is characteristic: worsening pain, intensified fatigue, amplified brain fog, heightened anxiety, disrupted sleep, and an overall sense of deterioration that does not follow the typical 'worse before better' adaptation pattern. Unlike the transient adjustment symptoms that most new LDN users experience during the first one to two weeks, these clients demonstrate persistent worsening that does not resolve with continued dosing or slower titration.

The standard clinical advice—start lower, go slower, wait longer—may not apply here, because the fundamental problem is not dose sensitivity or adaptation speed. The problem is insufficient endorphin reserve to support the rebound mechanism. You cannot upregulate a system that has nothing left to upregulate.

Clinical Implications: Framework-First, Medication-Second

This understanding has direct implications for clinical practice:

For ME/CFS: Begin with the SHINE framework. Restore sleep architecture, address hormonal deficiencies, treat active infections, optimize nutrition (with particular attention to mitochondrial support nutrients—CoQ10, D-ribose, B vitamins, magnesium), and implement graded exercise as tolerated. LDN is best introduced after foundational SHINE elements are in place, when the energy crisis has stabilized sufficiently to support endorphin system recovery.

For Long COVID: Implement the SHINE framework for the energy crisis dimension and a systematic MCAS protocol for the post-infectious immune dysregulation dimension. This dual approach recognizes Long COVID as the intersection of two distinct pathological processes. LDN can serve as a bridge between these frameworks, addressing both the neuroinflammatory component via TLR4 antagonism and the endorphin depletion component via receptor upregulation—but ideally when the underlying immune dysregulation is being concurrently managed.

For MCAS: Establish layered mast cell stabilization first—H1/H2 blockade, cromolyn, quercetin, and other stabilizers as appropriate—before introducing LDN. Reducing the inflammatory burden on the endorphin system before asking it to respond to transient blockade may improve the likelihood of a favorable LDN response.

For LDN-Intolerant Clients: Recognize that intolerance may signal severe endorphin depletion rather than medication sensitivity. These individuals may need endorphin system rehabilitation before LDN can work—through sleep restoration, stress reduction, gentle movement, mind-body practices, and targeted nutritional support for POMC/β-endorphin synthesis. Only after endorphin reserves have been partially replenished should LDN be carefully re-introduced, often at ultra-low doses (0.5 mg or below) with very gradual titration.

Conclusion: Comprehensive Care Over Pharmacological Shortcuts

LDN is a remarkable medication with genuine therapeutic utility across Long COVID, ME/CFS, and MCAS. The converging evidence from systematic reviews, mechanistic studies, and clinical experience supports its inclusion in the integrative treatment toolkit. But the seductive simplicity of 'one medication for three conditions' obscures a more nuanced clinical reality: each of these conditions demands its own dedicated framework, LDN works best as one component within that framework, and the very clients with the most severe disease—those with the deepest endorphin depletion—may be the ones who cannot tolerate the medication without prior system rehabilitation.

The lesson is not that LDN doesn't work. The lesson is that no medication works in isolation, and that the art of integrative medicine lies in understanding when and how to deploy each tool within a broader framework of comprehensive care.

References

1. Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332.

2. Byambasuren O, Atkins T, Baptista S, Glasziou P, Chakraborty S. Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis. BMJ Open. 2026;16(7):e111253.

3. Cabanas H, Muraki K, Eaton-Fitch N, Staines DR, Marshall-Gradisnik S. Potential therapeutic benefit of low dose naltrexone in myalgic encephalomyelitis/chronic fatigue syndrome: role of transient receptor potential melastatin 3 ion channels in pathophysiology and treatment. Front Immunol. 2021;12:687806.

4. Conti F, Pittoni V, Sacerdote P, et al. Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome. Clin Exp Rheumatol. 1998;16(6):729–732.

5. Panerai AE, Vecchiet J, Panzeri P, et al. Peripheral blood mononuclear cell beta-endorphin concentration is decreased in chronic fatigue syndrome and fibromyalgia but not in depression: preliminary report. Clin J Pain. 2002;18(4):270–273.

6. Polo O. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Fatigue Biomed Health Behav. 2019;7(4):207–217.

7. Teitelbaum J, Bird B, Greenfield R, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome and fibromyalgia—a randomized, double-blind, placebo-controlled, intent-to-treat study. J Chronic Fatigue Syndr. 2001;8(2):3–28.

8. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82.

9. Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long-COVID. Int J Infect Dis. 2021;112:217–226.

Related Reading from Dr. Kim

For readers who want to go deeper on the mechanisms and clinical decisions discussed above:

The Endorphin Depletion Hypothesis in CFS/ME

A deeper examination of the self-reinforcing cycle—chronic pain, non-restorative sleep, and endorphin depletion—that underlies the mechanism described above.

LDN, MCAS, and Why Individualized Dosing Matters

Why a single “standard” LDN dose fails in complex immune-mediated illness, and how titration must be tailored to the client—directly relevant to the intolerance paradox.

MCAS: A New Epidemic in Plain Sight

The common node linking Long COVID, Lyme disease, mold toxicity, and the modern chronic illness crisis—and how mast cell dysregulation drives them.

Low-Dose Naltrexone (LDN) in Functional Medicine: A Practical Guide

A foundational overview of LDN’s mechanism, clinical uses, and personalized dosing in integrative practice.

About Dr. Kim

Dr. Yoon Hang "John" Kim is a board-certified physician with over 20 years of experience in integrative and functional medicine. He completed fellowship training in Integrative Medicine at the University of Arizona under Dr. Andrew Weil, holds board certification in Preventive Medicine, and carries additional certifications in medical acupuncture and integrative/holistic medicine. Dr. Kim specializes in low dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold toxicity. He is the author of three books and more than 20 published articles on integrative medicine topics.

Professional: www.yoonhangkim.com  | 

Clinical: www.directintegrativecare.com

Disclaimer: This article is intended for educational and informational purposes only. It does not constitute medical advice. Please consult with a qualified healthcare provider before making changes to your treatment plan.